1
|
Yoshida K, Adachi T, Suzuki Y, Sakuwa M, Fukuda H, Hasegawa M, Adachi Y, Miura H, Hanajima R. Corticobasal degeneration with visual hallucination as an initial symptom: A case report. Neuropathology 2024. [PMID: 38291581 DOI: 10.1111/neup.12963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 01/11/2024] [Accepted: 01/12/2024] [Indexed: 02/01/2024]
Abstract
Although the initial symptoms of corticobasal degeneration (CBD) are varied, psychiatric symptoms are uncommon. Here, we report the autopsy findings of a patient with early CBD who presented with hallucinations. A 68-year-old man developed memory loss and visions of bears and insects. Because of slow vertical eye movement, postural instability, and levodopa-unresponsive parkinsonism, the patient initially was clinically diagnosed with progressive supranuclear palsy. He died of a urinary tract infection 11 months after the onset of the disease. Histopathological examination revealed neuronal loss and gliosis, which were severe in the substantia nigra and moderate in the globus pallidus and subthalamic nucleus. Astrocytic plaques were scattered throughout the amygdala and premotor cortex. The superficial cortical layers lacked ballooned neurons and spongiosis, and tau deposition was greater in glia than in neurons. The amygdala contained a moderate number of argyrophilic grains and pretangles. Western blot analysis showed a 37-kDa band among the low-molecular-weight tau fragments. Because the CBD pathology was mild, we attributed the patient's visual hallucinations to the marked argyrophilic grain pathology. CBD can occur with psychiatric symptoms, including visual hallucinations, and argyrophilic grain pathology may be associated with psychiatric symptoms.
Collapse
Affiliation(s)
- Kentaro Yoshida
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
- Department of Neurology, Matsue Red Cross Hospital, Matsue, Japan
| | - Tadashi Adachi
- Division of Neuropathology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Yuki Suzuki
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Mayuko Sakuwa
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Hiroki Fukuda
- Department of Neurology, Matsue Red Cross Hospital, Matsue, Japan
| | - Masato Hasegawa
- Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Yoshiki Adachi
- Department of Neurology, National Hospital Organization Matsue Medical Center, Matsue, Japan
| | - Hiroshi Miura
- Department of Pathology, Matsue Red Cross Hospital, Matsue, Japan
| | - Ritsuko Hanajima
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| |
Collapse
|
2
|
Sakuwa M, Adachi T, Suzuki Y, Yoshida K, Fukuda H, Miura H, Adachi Y, Hanajima R. First Japanese autopsy case showing LRRK2 mutation G2019S and TDP-43 proteinopathy. Parkinsonism Relat Disord 2021; 91:85-87. [PMID: 34543853 DOI: 10.1016/j.parkreldis.2021.09.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 09/07/2021] [Accepted: 09/12/2021] [Indexed: 11/16/2022]
Abstract
This is the first Japanese autopsy case of Leucine-rich repeat kinase 2 (LRRK2) G2019S mutation with atypical TDP43 proteinopathy. Our case is important that presented clinically dysphagia and pathologically TDP-43 proteinopathy. TDP43 may play an important role of clinical presentation with LRRK2 G2019S mutation carriers.
Collapse
Affiliation(s)
- Mayuko Sakuwa
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan
| | - Tadashi Adachi
- Division of Neuropathology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan.
| | - Yuki Suzuki
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan
| | - Kentaro Yoshida
- Department of Neurology, Japanese Red Cross Matsue Hospital, Shimane, Japan
| | - Hiroki Fukuda
- Department of Neurology, Japanese Red Cross Matsue Hospital, Shimane, Japan
| | - Hiroshi Miura
- Department of Pathology, Japanese Red Cross Matsue Hospital, Shimane, Japan
| | - Yoshiki Adachi
- Department of Neurology, National Hospital Organization Matsue Medical Center, Shimane, Japan
| | - Ristuko Hanajima
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan
| |
Collapse
|
3
|
Matsumura T, Takada H, Kobayashi M, Nakajima T, Ogata K, Nakamura A, Funato M, Kuru S, Komai K, Futamura N, Adachi Y, Arahata H, Fukudome T, Ishizaki M, Suwazono S, Aoki M, Matsuura T, Takahashi MP, Sunada Y, Hanayama K, Hashimoto H, Nakamura H. A web-based questionnaire survey on the influence of coronavirus disease-19 on the care of patients with muscular dystrophy. Neuromuscul Disord 2021; 31:839-846. [PMID: 34462178 PMCID: PMC8102088 DOI: 10.1016/j.nmd.2021.04.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 02/09/2021] [Accepted: 04/29/2021] [Indexed: 11/08/2022]
Abstract
To clarify the influence of coronavirus disease-19 (COVID-19) on the care of muscular dystrophy patients, we performed a questionnaire survey that was posted on the internet on May 11, 2020. By the end of July 2020, 542 responses had been collected. Approximately 30% of patients postponed regular consultations, and one-quarter of patients who received consultation more than once a month used telephone consultations. Two of 84 patients with Duchenne muscular dystrophy had reduced their steroid doses. A shortage of ventilator accessories and infection protection equipment occurred following the onset of COVID-19, and this shortage had a serious impact on medical care and infection prevention measures. Reductions in rehabilitation and other services, and avoidance of outings, led to a decrease in exercise and an increase in caregiver burden. Inpatients were restricted from going out and visiting family members. More than 20% of patients reported physical or mental complaints; however, few required treatment. COVID-19 has seriously affected the activities and quality of life of patients with muscular dystrophy. We will continue this survey and analyze the longitudinal changes.
Collapse
Affiliation(s)
- Tsuyoshi Matsumura
- Dept. of Neurology, NHO Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552, Japan.
| | - Hiroto Takada
- Dept. of Neurology, NHO Aomori Hosp., 155-1 Namioka Megasawa Hirano, Aomori, 038-1331, Japan
| | - Michio Kobayashi
- Dept. of Neurology, NHO Akita Hosp., 3-52 Iwakiuchi Michikawa Idonosawa, Yurihonjo, Akita 018-1393, Japan
| | - Takashi Nakajima
- Dept. of Neurology, NHO Niigata Hosp., 3-52 Akasaka-cho, Kashiwazaki, Niigata 945-8585, Japan
| | - Katsuhisa Ogata
- Dept. of Clinical Research, NHO Higashisaitama Hosp., Kurohama 4147, Hasuda, Saitama 349-0196, Japan
| | - Akinori Nakamura
- Dept. of Clinical Research, NHO Matsumoto Medical Center, 2-20-30 Muraimachi-minami, Matsumoto, Nagano 399-8701, Japan
| | - Michinori Funato
- Dept. of Pediatrics, NHO Nagara Medical Center, 1300-7 Nagara, Gifu, 502-8558, Japan
| | - Satoshi Kuru
- Dept. of Neurology, NHO Suzuka Hosp., 3-2-1 Kasado, Suzuka, Mie 513-8501, Japan
| | - Kiyonobu Komai
- Dept. of Neurology, NHO Iou Hosp., 2-73-1 Iwade-machi, Kanazawa, Ishikawa 920-0171, Japan
| | - Naonobu Futamura
- Dept. of Neurology, NHO Hyogo-Chuo Hosp., 1314 Ohara, Sanda, Hyogo 669-1516, Japan
| | - Yoshiki Adachi
- Dept. of Clinical Research, NHO Matsue Medical Center, 5-8-31 Agenoki, Matsue, Shimane 690-8556, Japan
| | - Hajime Arahata
- Dept. of Neurology, NHO Omuta Hosp., 1044-1 Tachibana, Omuta, Fukuoka 837-0911, Japan
| | - Takayasu Fukudome
- Dept. of Neurology, NHO Nagasaki Kawatana Medical Center, 2005-1 Shimogumigo, Kawatana, Nagasaki 859-3615, Japan
| | - Masatoshi Ishizaki
- Dept. of Neurology, NHO Kumamoto Saishunso Medical Center, 2659 Suya, Goushi, Kumamoto 861-1196, Japan
| | - Shugo Suwazono
- Dept. of Neurology, NHO Okinawa Hosp., 3-20 Ganeko, Ginowan, Okinawa 901-2214, Japan
| | - Masashi Aoki
- Dept. of Neurology, Tohoku Univ. School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan
| | - Tohru Matsuura
- Dept. of Neurology, Jichi Medical Univ., 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
| | - Masanori P Takahashi
- Dept. of Functional Diagnostic Science, Osaka Univ. Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Yoshihide Sunada
- Dept. of Neurology, Kawasaki Medical School, 57 Matsushima, Kurashiki, Okayama 701-0192, Japan
| | - Kouzou Hanayama
- Dept of Rehabilitation, Kawasaki Medical School, 57 Matsushima, Kurashiki, Okayama 701-0192, Japan
| | - Hiroya Hashimoto
- Clinical Research Management Center, Nagoya City Univ. Hosp., 1 Kawasumi Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-0001, Japan
| | - Harumasa Nakamura
- TMC, National Center of Neurology, Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-0031, Japan
| |
Collapse
|
4
|
Sakuwa M, Adachi T, Yoshida K, Adachi Y, Nakano T, Hanajima R. An autopsy case of PARK2 due to a homozygous exon 2 deletion of parkin and associated with α-synucleinopathy. Neuropathology 2021; 41:293-300. [PMID: 34121225 DOI: 10.1111/neup.12735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Revised: 01/20/2021] [Accepted: 01/30/2021] [Indexed: 11/29/2022]
Abstract
Lewy bodies (LBs) are usually detected in patients with idiopathic Parkinson's disease (PD), but there have been few reports of LBs in a familial form of early-onset PD associated with several mutations in parkin, a gene that encodes a ubiquitin E3 ligase involved in mitochondrial homeostasis, being also known as PARK2. Here, we report a case of PD with a PARK2 mutation characterized by a homozygous deletion of exon 2 and incidental LB pathology. A 60-year-old man developed tremor in the upper limbs. Although levodopa was initially effective, his symptoms slowly progressed. His cardiac uptake of 123 I-metaiodobenzylguanidine, as assessed by myocardial scintigraphy, decreased from an early stage after the onset. At the age of 81 years, he developed Legionella pneumonia and died of respiratory failure. Histopathological examination revealed a moderate loss of pigmented neurons, as well as gliosis in the substantia nigra and the locus coeruleus. Little LB-related pathology was found in the locus coeruleus, dorsal nucleus of vagal nerve, and basal nucleus of Meynert. The cardiac sympathetic nerve in the epicardium showed a reduction in the numbers of fibers immunoreactive for tyrosine hydroxylase and phosphorylated neurofilament protein. Genetic analysis of frozen brain materials revealed a homozygous deletion of exon 2 of parkin. To our knowledge, this is the first autopsy case with a homozygous deletion of exon 2 of parkin. The number of LBs was small, the age of disease onset was later than that in typical PARK2-associated PD patients, and cardiac sympathetic denervation was also present. Thus, we considered the LBs in our case as incidental and preclinical α-synucleinopathy.
Collapse
Affiliation(s)
- Mayuko Sakuwa
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Tadashi Adachi
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.,Division of Neuropathology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Kentaro Yoshida
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Yoshiki Adachi
- Department of Neurology, National Hospital Organization Matsue Medical Center, Matsue, Japan
| | - Toshiya Nakano
- Department of Neurology, National Hospital Organization Matsue Medical Center, Matsue, Japan
| | - Ritsuko Hanajima
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| |
Collapse
|
5
|
Suzuki T, Adachi Y, Ohgaki T, Sakaguchi I. Crystal plane‐dependent ethanol gas sensing of ZnO studied by low‐energy He
+
ion scattering combined with pulsed jet technique. SURF INTERFACE ANAL 2021. [DOI: 10.1002/sia.6974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- T.T. Suzuki
- National Institute for Materials Science Tsukuba Japan
| | - Y. Adachi
- National Institute for Materials Science Tsukuba Japan
| | - T. Ohgaki
- National Institute for Materials Science Tsukuba Japan
| | - I. Sakaguchi
- National Institute for Materials Science Tsukuba Japan
| |
Collapse
|
6
|
Nagasaka T, Hata T, Shindo K, Adachi Y, Takeuchi M, Saito K, Takiyama Y. Morphological Alterations of the Sarcotubular System in Permanent Myopathy of Hereditary Hypokalemic Periodic Paralysis with a Mutation in the CACNA1S Gene. J Neuropathol Exp Neurol 2021; 79:1276-1292. [PMID: 33184660 DOI: 10.1093/jnen/nlaa098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
We investigated the immunohistochemical localization of several proteins related to excitation-contraction coupling and ultrastructural alterations of the sarcotubular system in biopsied muscles from a father and a daughter in a family with permanent myopathy with hypokalemic periodic paralysis (PMPP) due to a mutation in calcium channel CACNA1S; p. R1239H hetero. Immunostaining for L-type calcium channels (LCaC) showed linear hyper-stained regions indicating proliferation of longitudinal t-tubules. The margin of vacuoles was positive for ryanodine receptor, LCaC, calsequestrin (CASQ) 1, CASQ 2, SR/ER Ca2+-ATPase (SERCA) 1, SERCA2, dysferlin, dystrophin, α-actinin, LC3, and LAMP 1. Electron microscopy indicated that the vacuoles mainly originated from the sarcoplasmic reticulum (SR). These findings indicate impairment of the muscle contraction system related to Ca2+ dynamics, remodeling of t-tubules and muscle fiber repair. We speculate that PMPP in patients with a CACNA1S mutation might start with abnormal SR function due to impaired LCaC. Subsequent induction of muscular contractile abnormalities and the vacuoles formed by fused SR in the repair process including autophagy might result in permanent myopathy. Our findings may facilitate prediction of the pathomechanisms of PMPP seen on morphological observation.
Collapse
Affiliation(s)
- Takamura Nagasaka
- Department of Neurology, Faculty of Medicine, University of Yamanashi, Chuou-city, Yamanashi, Japan
| | - Takanori Hata
- Department of Neurology, Faculty of Medicine, University of Yamanashi, Chuou-city, Yamanashi, Japan
| | - Kazumasa Shindo
- Department of Neurology, Faculty of Medicine, University of Yamanashi, Chuou-city, Yamanashi, Japan
| | - Yoshiki Adachi
- Department of Neurology, Matsue Medical Center, National Hospital Organization, Shimane, Japan
| | | | - Kayoko Saito
- Institute of Medical Genetics, Tokyo Women's University, Tokyo, Japan
| | - Yoshihisa Takiyama
- Department of Neurology, Faculty of Medicine, University of Yamanashi, Chuou-city, Yamanashi, Japan
| |
Collapse
|
7
|
Panova I, Ilyasov L, Khaidapova D, Bashina A, Smagin A, Ogawa K, Adachi Y, Yaroslavov A. Soil conditioners based on anionic polymer and anionic micro-sized hydrogel: A comparative study. Colloids Surf A Physicochem Eng Asp 2021. [DOI: 10.1016/j.colsurfa.2020.125635] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
8
|
Liu P, Fukuma N, Hiroi Y, Ueda K, Kariya T, Numata G, Adachi Y, Toyoda M, Li Y, Noma K, Toko H, Kanai Y, Takimoto E, Liao J, Komuro I. Endothelial-specific Ablation of Non-nuclear Estrogen Receptor alpha Signaling Deteriorates Vascular Remodelling Response. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background and introduction
The difference in cardiovascular disease risk between age-matched women and men narrows as transition through menopause in observational studies. Estrogen exerts complex physiological effects via its non-nuclear and nuclear actions. Experimental studies have shown that endothelial estrogen receptors mediate vasoprotection via endothelial nitric oxide production, reendothelialization, and atherosclerosis. Prior studies in vitro addressed estrogen's effects on endothelial cells and vascular smooth muscle cells, leading to vasoprotection. However, the in vivo evidences are lacking for beneficial effects of endothelium non-nuclear ERα signaling on vascular remodelling in response to injury.
Purpose
This study aims to clarify the impact of endothelial ERα non-nuclear signaling in the vasoprotection, using a novel mouse model lacking tissue-specific ERα non-nuclear signaling.
Methods
We identified the amino acids of ERα which were responsible for its binding to p85α subunit of phosphatidylinositol 3-kinase in vitro. We generated a novel mouse model in which non-nuclear signaling of ERα was ablated in endothelial cells by crossing Tie2-Cre transgenic mice with floxed ERα mutants (RR259/260AA) in which p85α and ERα interaction was disrupted.
Results
In endothelial cells isolated from ERαKI/KITie2 cre/+ animals, E2 failed to induce phosphorylation of Akt, confirming the absence of ERα non-nuclear signaling. Baseline characteristics at 8 to 12 weeks of age were undistinguishable between the genotypes, including body weight, systolic blood pressure, uterine weight and echocardiographic fractional shortening. We then assessed how vascular remodelling process was impacted in a carotid artery wire injury model. Histological analyses with Elastica van Gieson staining two weeks after injury revealed that estrogen dependent suppression of remodelling response (intima to medial ratio) was abolished in ERαki/kiTie2cre/+mice (P=0.0004). Masson's Trichrome staining showed that in the presence of E2 fibrosis was significantly higher in ERαki/kiTie2cre/+ mice than ERαki/kiTie2cre/− mice (P=0.0015).
Conclusions
We generated a novel mouse model for tissue-specific ablation of ERα non-nuclear signaling by interfering ERα-PI3K interaction. Our results demonstrate that the pivotal role for ERα non-nuclear signaling of endothelial cells in carotid arterial protection following injury with its minimal impact on baseline cardiovascular phenotype.
Funding Acknowledgement
Type of funding source: Foundation. Main funding source(s): Japan Heart Foundation Research Grant, SENSHIN Medical Research Foundation
Collapse
Affiliation(s)
- P.Y Liu
- National Defense Medical Center, Tri-Service General Hospital, Cardiology, Taipei, Taiwan
| | - N Fukuma
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - Y Hiroi
- National Center for Global Health and Medicine, Tokyo, Japan
| | - K Ueda
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - T Kariya
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - G Numata
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - Y Adachi
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - M Toyoda
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - Y Li
- Nihon University School of Medicine, Tokyo, Japan
| | - K Noma
- Research Institute for Radiation Biology and Medicine, Hiroshima, Japan
| | - H Toko
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - Y Kanai
- Wakayama Medical University, Wakayama, Japan
| | - E Takimoto
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| | - J.K Liao
- University of Chicago Medical Center, Department of Medicine, Section of Cardiology, Chicago, United States of America
| | - I Komuro
- University of Tokyo, Cardiovascular Medicine, Tokyo, Japan
| |
Collapse
|
9
|
Panova IG, Ilyasov LO, Khaidapova DD, Ogawa K, Adachi Y, Yaroslavov AA. Polyelectrolytic Gels for Stabilizing Sand Soil against Wind Erosion. Polym Sci Ser B 2020. [DOI: 10.1134/s1560090420050103] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
10
|
Lee CH, Adachi Y, Ikezawa H, Li S, Funahashi Y, Minoshima Y, Kubiak P, Perini R, Ren M, Smith A, Motzer R. 719P Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, Kouno S, Taniguchi Y, Saijo N, Okishio K, Atagi S. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. Clin Transl Oncol 2020; 23:582-590. [PMID: 32661824 DOI: 10.1007/s12094-020-02452-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 07/04/2020] [Indexed: 12/15/2022]
Abstract
PURPOSE This study evaluated the efficacy and safety of nivolumab treatment beyond progressive disease (PD) in non-small cell lung cancer (NSCLC). PATIENTS/METHODS Medical records of consecutive patients with advanced NSCLC who received nivolumab between December 2015 and December 2018 were reviewed. Clinical outcomes of three groups of eligible patients who received nivolumab as a second-line treatment after PD were compared based on Response Evaluation Criteria in Solid Tumors v1.1. We conducted subgroup analyses in patients with and without new lesions at first PD. RESULTS Twenty-eight patients continued nivolumab treatment beyond PD (TBP). Post PD, 46 patients switched to other anti-cancer treatment (OAT), and 21 received no further anti-cancer treatment (NAT). There were no significant differences in overall survival (OS) or survival post progression (SPP) between TBP and OAT groups (OS: 15.6 vs. 13.4 months, P = .40, SPP: 12.2 vs. 9.3 months, P = .42). Subgroup analyses indicated that among patients without new lesions at first PD, SPP was longer in the TBP than in the OAT groups (12.6 vs. 9.3 months, P = .22, HR: 0.64; 95% CI 0.31‒1.31). The frequency of immune-related adverse events leading to discontinuation during nivolumab beyond PD was equivalent to that for pre-PD (10.7 vs. 12.6%). CONCLUSIONS No significant benefits were associated with continuation of nivolumab for advanced NSCLC patients. Continuation of nivolumab beyond PD could be a more useful option in patients without new lesions at first PD. Treatment-related toxicities require attention during nivolumab treatment not only before PD but also beyond PD.
Collapse
Affiliation(s)
- T Enomoto
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
| | - A Tamiya
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - K Matsumoto
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - Y Adachi
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - K Azuma
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - Y Inagaki
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - S Kouno
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - Y Taniguchi
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - N Saijo
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - K Okishio
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| | - S Atagi
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
| |
Collapse
|
12
|
Yukihira N, Yamashita T, Adachi Y, Kawamura A, Hori H, Gunji Y, Fukuchi T, Sugawara H. A Rare Case of Pyogenic Spondylitis Caused by Aggregatibacter Actinomycetemcomitans. J Infect Public Health 2020. [DOI: 10.1016/j.jiph.2020.01.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
13
|
Sawada J, Katayama T, Tokashiki T, Kikuchi S, Kano K, Takahashi K, Saito T, Adachi Y, Okamoto Y, Yoshimura A, Takashima H, Hasebe N. The First Case of Spinocerebellar Ataxia Type 8 in Monozygotic Twins. Intern Med 2020; 59:277-283. [PMID: 31554751 PMCID: PMC7008061 DOI: 10.2169/internalmedicine.2905-19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Spinocerebellar ataxia type 8 (SCA8) is a rare hereditary cerebellar ataxia showing mainly pure cerebellar ataxia. We herein report cases of SCA8 in Japanese monozygotic twins that presented with nystagmus, dysarthria, and limb and truncal ataxia. Their ATXN8OS CTA/CTG repeats were 25/97. They showed similar manifestations, clinical courses, and cerebellar atrophy on magnetic resonance imaging. Some of their pedigrees had nystagmus but not ataxia. These are the first monozygotic twins with SCA8 to be reported anywhere in the world. Although not all subjects with the ATXN8OS CTG expansion develop cerebellar ataxia, these cases suggest the pathogenesis of ATXN8OS repeat expansions in hereditary cerebellar ataxia.
Collapse
Affiliation(s)
- Jun Sawada
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| | - Takayuki Katayama
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| | - Takashi Tokashiki
- Department of Neurology, National Hospital Organization Okinawa Hospital, Japan
| | - Shiori Kikuchi
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| | - Kohei Kano
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| | - Kae Takahashi
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| | - Tsukasa Saito
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| | - Yoshiki Adachi
- Department of Neurology, National Hospital Organization Matsue Medical Center, Japan
| | - Yuji Okamoto
- Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Japan
| | - Akiko Yoshimura
- Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Japan
| | - Hiroshi Takashima
- Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Japan
| | - Naoyuki Hasebe
- Division of Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
| |
Collapse
|
14
|
Azuma K, Tamiya A, Adachi Y, Enomoto T, Kouno S, Taniguchi Y, Saijo N, Okishio K, Atagi S. Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz449.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, Kouno S, Taniguchi Y, Saijo N, Okishio K, Atagi S. Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz449.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Sasaki T, Kawabata S, Hoshino Y, Sekihara K, Akaza M, Ozaki I, Adachi Y, Hasegawa Y, Sato S, Watanabe T, Okawa A. Visualization of electrophysiological activity in patients with carpal tunnel syndrome using magnetoneurography. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Adachi Y, Tamiya A, Taniguchi Y, Enomoto T, Azuma K, Kouno S, Saijo N, Okishio K, Atagi S. P2.01-60 Analysis of Prognostic Factors According to Performance Status in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Sumiya S, Kawabata S, Ushio S, Sasaki T, Hashimoto J, Hoshino Y, Sekihara K, Watanabe T, Adachi Y, Okawa A. Visualization of electrophysiological activity in the cervical spinal cord using magnetospinography. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Kaminaka S, Akaza M, Kawabata S, Watanabe T, Miyano Y, Iida S, Sasaki T, Adachi Y, Sekihara K, Kanouchi T, Sumi Y, Okawa A, Yokota T. Diagnosis of C8 radiculopathy by magnetospinogram. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Kano S, Nasu K, Habara M, Shimura T, Yamamoto M, Adachi Y, Konishi H, Kodama A, Koshida R, Kinoshita Y, Tsuchikane E, Terashima M, Matsubara T, Suzuki T. 124Impact of intimal tracking for recanalization of CTO lesions on long-term clinical outcomes. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
For recanalization of coronary chronic total occlusion (CTO) lesions, subintimal guidewire tracking in both antegrade and retrograde approaches are commonly used.
Purpose
This study aimed to assess the impact of subintimal tracking on long-term clinical outcomes after recanalization of CTO lesions.
Methods
Between January 2009 and December 2016, 474 CTO lesions (434patients) were successfully recanalized in our center. After guidewire crossing in a CTO lesion, those lesions were divided into intimal tracking group (84.6%, n=401) and subintimal tracking group (15.4%, n=73) according to intravascular ultrasound (IVUS) findings. Long-term clinical outcomes including death, target lesion revascularization (TLR), target vessel revascularization (TVR) were compared between the two groups. In addition, the rate of re-occlusion after successful revascularization was also evaluated.
Results
The median follow-up period was 4.7 years (interquartile range, 2.8–6.1). There was no significant difference of the rate of cardiac death between the two groups (intimal tracking vs. subintimal tracking: 7.0% vs. 4.1%; hazard ratio, 0.61; 95% confidence interval [CI], 0.19 to 2.00; p=0.41), TLR (14.3% vs. 16.2%; hazard ratio, 1.34; 95% CI, 0.71 to 2.53; p=0.37), and TVR (17.5% vs. 20.3%; hazard ratio, 1.27; 95% CI, 0.72 to 2.23; p=0.42). However, the rate of re-occlusion was significantly higher in the subintimal tracking group than intimal tracking group at 3-years re-occlusion (4.2% vs. 14.5%; log-rank test, p=0.002, Figure). In the multivariate COX regression, subintimal guidewire tracking was an independent predictor of re-occlusion after CTO recanalization (HR: 5.40; 95% CI: 2.11–13.80; p<0.001).
Figure 1
Conclusions
Subintimal guidewire tracking for recanalization of coronary CTO was associated with significantly higher incidence of target lesion re-occlusion during long-term follow-up period.
Collapse
Affiliation(s)
- S Kano
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - K Nasu
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - M Habara
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - T Shimura
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - M Yamamoto
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - Y Adachi
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - H Konishi
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - A Kodama
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - R Koshida
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - Y Kinoshita
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - E Tsuchikane
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - M Terashima
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - T Matsubara
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| | - T Suzuki
- Toyohashi Heart Center, cardiovascular medicine, Toyohashi, Japan
| |
Collapse
|
21
|
Watanabe T, Kawabata S, Hoshino Y, Sasaki T, Ushio S, Akaza M, Miyano Y, Ozaki I, Adachi Y, Sekihara K, Okawa A. Visualization of nerve activities along the brachial plexus after median/ulnar nerve stimulation using magnetoneurography system. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Kawabata S, Sasaki T, Hoshino Y, Sekihara K, Adachi Y, Watanabe T, Miyano Y, Okawa A. Diagnosis of conduction block in cervical myelopathy patients by non-invasive magnetospinography. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Kimu S, Kawabata S, Akaza M, Sekihara K, Hoshino Y, Sasaki T, Watanabe T, Miyano Y, Sato S, Mitani Y, Yamaga T, Adachi Y, Okawa A. Visualization of neural activities in lumbar spine in response to the sciatic nerve stimulation by magnetoneurography. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Nishibuchi I, Murakami Y, Adachi Y, Imano N, Takeuchi Y, Takahashi I, Kimura T, Nagata Y. Long-term Results of Definitive Chemoradiotherapy with Elective Nodal Irradiation Using Modern Radiotherapy Technique for Resectable Locally Advanced Esophageal Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Mori M, Sawaki M, Hattori M, Yoshimura A, Gondo N, Kotani H, Adachi Y, Kataoka A, Sugino K, Iwata H. Microdochectomy experience for patients with nipple discharge from a single institution. Breast 2019. [DOI: 10.1016/s0960-9776(19)30368-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
26
|
Adachi Y, Akino K, Nojima M, Himori R, Kikuchi T, Mita H, Nakamura M, Tsukuda H, Yamano HO, Sasaki Y, Yoshida Y, Kato Y, Nakase H, Endo T. Prognostic nutritional index and early mortality with percutaneous endoscopic gastrostomy. QJM 2018; 111:635-641. [PMID: 29939360 DOI: 10.1093/qjmed/hcy137] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Although percutaneous endoscopic gastrostomy (PEG) is a well-accepted and less invasive method of feeding tube placement in patients with swallowing difficulties, complications and early death after PEG have been reported. AIM This study aimed to evaluate predictive factors associated with 30-day mortality after PEG, and to assess the utility of nutritional supporting period before PEG in reducing early mortality following PEG. DESIGN An observational study. METHODS We retrospectively analyzed 268 patients who underwent PEG at Sapporo Shirakaba-dai Hospital from 2006 to 2010, using clinical and laboratory data to analyze predictive factors associated with early death after PEG. Then, we prospectively assessed 152 consecutive patients assessed for eligibility for PEG from 2011 to 2014. We assessed the patients' nutritional condition using Onodera's prognostic nutritional index (PNI), and supported nutrition for more than 10 days before PEG in patients with a poor nutritional index (PNI < 37). RESULTS In both univariate and multivariate analyses in the retrospective study, Onodera's PNI of less than 37 was the only predictive factor for early mortality. In the second study, among the 115 patients who finally underwent PEG, early mortality rates improved to 1.7% from 5.2% in the first study. Conversely, 32% of patients with malnutrition who did not undergo PEG died within 30 days. CONCLUSION Nutritional status might be a predictive factor for early mortality after PEG. In patients with poor nutritional status, nutritional supporting period before PEG might improve the outcomes and reduce unnecessary PEG.
Collapse
Affiliation(s)
- Y Adachi
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - K Akino
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - M Nojima
- Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan
| | - R Himori
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - T Kikuchi
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - H Mita
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - M Nakamura
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - H Tsukuda
- Department of Internal Medicine, Sapporo Shirakaba-dai Minami Hospital, Sapporo, Japan
| | - H-O Yamano
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - Y Sasaki
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - Y Yoshida
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - Y Kato
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| | - H Nakase
- Department of Gastroenterology, Sapporo Medical University, Sapporo, Japan
| | - T Endo
- From the Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan
| |
Collapse
|
27
|
Hattori M, Nakanishi H, Yoshimura A, Adachi Y, Iwase M, Gondo N, Kotani H, Sawaki M, Yatabe Y, Iwata H. Abstract P2-01-09: Circulating tumor cells (CTCs) in the venous drainage of the breast in patients with primary breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-01-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
CTCs are shed from tumors and circulate in the peripheral blood after passing through the drainage vein. Axillary lymph node dissection (ALND) provides access to the lateral thoracic vein which flows directly into the axillary vein. In this preliminary study, we evaluated the feasibility of detecting CTCs in the peripheral blood and in the lateral thoracic venous blood for breast cancer patients who underwent ALND.
Methods:
From June 2016 to March 2017, breast cancer patients who underwent ALND in our institute were eligible for this study. A peripheral blood sample,10ml, was drawn just before the surgery or one day before the surgery. A lateral thoracic venous blood sample was taken from the resected breast just after resection. A blood sample of 0.2ml or more was necessary for CTC isolation. The CTCs in the peripheral blood before surgery (periCTC) and in the blood from the lateral thoracic vein of the resected breast (ltvCTC) were quantitatively examined by using a size-selective CTC isolation platform.
Results:
A total of 21 patients with median age 51 years (37-75) were enrolled to the study. Of the 21 patients, 38% were premenopausal, 52% had neoadjuvant chemotherapy. Fifty-seven percent were ER and/or PgR positive, 24% were HER2 positive. Fifty-seven percent were stage II disease and 43% were stage III. In 3 patients, we couldn't obtain sufficient blood samples from the lateral thoracic vein. Of the remaining 18 patients, we were able to obtain the median 0.5ml (0.2-2.0) blood samples from the lateral thoracic vein. CTCs were detected in peripheral blood in 15 patients (71%) and median periCTC count was 1 CTC/10ml (0-39). In lateral thoracic venous blood, CTCs were detected in all patients who had sufficient blood samples and the median ltv CTC count was 35.5 CTC/ml (2.5-370). In 5 of 6 patients whom CTCs in peripheral blood samples were not detected, CTCs could be detected in the blood samples from lateral thoracic vein.
Conclusion:
CTCs can be detected in the peripheral blood and in the blood from lateral thoracic vein in patients with localized breast cancer, and can be detected at a higher rate and at a higher concentration in the blood from lateral thoracic vein than in peripheral blood.
Citation Format: Hattori M, Nakanishi H, Yoshimura A, Adachi Y, Iwase M, Gondo N, Kotani H, Sawaki M, Yatabe Y, Iwata H. Circulating tumor cells (CTCs) in the venous drainage of the breast in patients with primary breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-01-09.
Collapse
Affiliation(s)
- M Hattori
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - H Nakanishi
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - A Yoshimura
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - Y Adachi
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - M Iwase
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - N Gondo
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - H Kotani
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - M Sawaki
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - Y Yatabe
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - H Iwata
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| |
Collapse
|
28
|
Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Iwase M, Oonishi S, Kataoka A, Adachi Y, Gondou N, Yoshimura A, Hattori M, Sawaki M, Iwata H. Abstract P2-12-13: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-12-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- H Kotani
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Terada
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Mori
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - N Horisawa
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - K Sugino
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Iwase
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - S Oonishi
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - A Kataoka
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - Y Adachi
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - N Gondou
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - A Yoshimura
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Hattori
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Sawaki
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - H Iwata
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| |
Collapse
|
29
|
Watanabe T, Kawabata S, Akaza M, Adachi Y, Sekihara K, Okawa A. Visualizaton of neural activities in brachial plexus by magnetoneurography. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Yoshikawa H, Iwasa K, Adachi Y, Edahiro S, Maruta T, Furukawa Y, Masahito Y, Matsui M. Ten-year chronological clinical profiles of myasthenia Gravis in Japan -epidemiological analyses of the national database established by the policy of intractable diseases of Japan. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.223] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Toyoshima K, Nakamura M, Hakamada T, Adachi Y, Imaizumi A, Abe Y, Kaneko E, Shimokado K. INCREASED PLASMA PROLINE CONCENTRATION IS ASSOCIATED WITH SARCOPENIA OF ELDERLY PEOPLE. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K. Toyoshima
- Tokyo Medical and Dental University, Tokyo, Japan,
| | - M. Nakamura
- Tokyo Medical and Dental University, Tokyo, Japan,
| | - T. Hakamada
- Tokyo Medical and Dental University, Tokyo, Japan,
| | - Y. Adachi
- Institute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan
| | - A. Imaizumi
- Institute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan
| | - Y. Abe
- Tokyo Medical and Dental University, Tokyo, Japan,
| | - E. Kaneko
- Tokyo Medical and Dental University, Tokyo, Japan,
| | - K. Shimokado
- Tokyo Medical and Dental University, Tokyo, Japan,
| |
Collapse
|
32
|
Kimura T, Adachi Y, Matsuki M, Yamaguchi A, Ozawa Y, Okamoto K, Mitsuhashi K, Hoshi T, Tohyama O, Tai K, Ogo M, Matsui J, Funahashi Y. The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Adachi Y, Satokawa C, Saeki M, Ohno N, Tamura H, Tanaka S, Yadomae T. Inhibition by a CD14 monoclonal antibody of lipopolysaccharide binding to murine macrophages. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/09680519990050030701] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We have established an anti-CD14 mAb named 4C1 against murine macrophages. 4C1 can bind to thioglycolate-elicited peritoneal macrophages, bone marrow-derived macrophages and casein-induced peritoneal neutrophils. Immunostaining with 4C1 was inhibited by treatment of the cells with phosphatidylinositol specific phospholipase C, suggesting that the antigen is GPI-anchored. Immunoprecipitates from biotin-labeled RAW264.7 cell lysate with 4C1 were around 55 kDa and were visualized with rmC5-3, the only commercially available anti-murine CD14 mAb. 4C1 positively stained COS7 cells transfected with an expression vector containing cDNA of murine CD14. Pretreatment of macrophages with 4C1 reduced LPS-mediated production of TNFα, IL-6, and nitrite. The binding of FITC-LPS to RAW264.7 cells was blocked by pretreatment with 4C1 but not with rmC5. Pretreatment of cells with unlabeled 4C1 mAb but not unlabeled rmC5-3 reduced binding of FITC-4C1. These results suggest that the 4C1 epitope on murine CD14 plays an important role in LPS binding and is distinct from the rmC5-3 epitope.
Collapse
Affiliation(s)
- Y. Adachi
- Laboratory of Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan,
| | - C. Satokawa
- Laboratory of Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan
| | - M. Saeki
- Laboratory of Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan
| | - N. Ohno
- Laboratory of Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan
| | - H. Tamura
- Seikagaku Corporation, Tokyo Institute, Tokyo, Japan
| | - S. Tanaka
- Seikagaku Corporation, Tokyo Institute, Tokyo, Japan
| | - T. Yadomae
- Laboratory of Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan
| |
Collapse
|
34
|
Watanabe Y, Beeldman E, Raaphorst J, Izumi Y, Yoshino H, Masuda M, Atsuta N, Ito S, Adachi T, Adachi Y, Yokota O, Oda M, Hanashima R, Ogino M, Ichikawa H, Hasegawa K, Kimura H, Shimizu T, Aiba I, Yabe H, Kanba M, Kusumi K, Aoki T, Hiroe Y, Watanabe H, Nishiyama K, Nomoto M, Sobue G, Nakashima K. Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J). J Neurol Sci 2016; 367:51-5. [DOI: 10.1016/j.jns.2016.05.036] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 04/18/2016] [Accepted: 05/17/2016] [Indexed: 10/21/2022]
|
35
|
Inoue K, Takano H, Oda T, Yanagisawa R, Tamura H, Ohno N, Adachi Y, Ishibashi K, Yoshikawa T. Candida Soluble Cell Wall β-D-Glucan Induces Lung Inflammation in Mice. Int J Immunopathol Pharmacol 2016; 20:499-508. [PMID: 17880763 DOI: 10.1177/039463200702000308] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Bioactivity of cell wall component(s) of fungi has not been fully elucidated, especially in vivo. We isolated Candida soluble beta-D-glucan (CSBG) from Candida albicans (C. albicans). We investigated the effects of airway exposure to CSBG on the immune systems in the airways in mice. CSBG exposure induced neutrophilic and eosinophilic inflammation in the lung, which was concomitant with the increased local expression of proinflammatory cytokines including tumor necrosis factor - α, interleukin (IL)-1 β, IL-6, macrophage inflammatory protein -1 α, macrophage chemoattractant protein -1, RANTES (regulated on activation and normal T cells expressed and secreted), and eotaxin. The lung inflammation with enhanced expression of proinflammatory proteins caused by CSBG was directly related to its structure, since structurally degraded products of CSBG by formic acid induced negligible responses in the lung. CSBG enhanced nuclear localization of phosphorylated signal transducer and activator of transcription (STAT)-6 in the lung. These results suggest that airway exposure to CSBG induces lung inflammation, at least partly, via the enhanced expression of proinflammatory cytokines and the activation of STAT-6 pathway, and can be a proper murine model for fungal lung inflammation.
Collapse
Affiliation(s)
- K Inoue
- Environmental Health Sciences Division, National Institute for Environmental Studies, Tsukuba, Ibaraki, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Matsunaga T, Hayashi N, Adachi Y, Nozue M. SU-G-TeP2-03: Comparison of Standard Dosimetry Protocol in Japan and AAPM TG-51 Addendum in Order to Establish Optimal Dosimetry for FFF Beam. Med Phys 2016. [DOI: 10.1118/1.4957038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
37
|
Adachi Y, Magaribuchi T, Nakano Y, Takao N, Watanabe J, Shirahase T, Sakatani T, Taki Y, Takeuchi H, Li M, Ikehara S. Analyses of combined prostate cancer in resected specimens by total cystectomy due to urinary bladder cancer. Eur J Cancer 2016. [DOI: 10.1016/j.ejca.2016.03.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Sugimoto T, Kobayashi M, Adachi Y. Orthokinetic aggregation of charged colloidal particles in the presence of repulsive double layer force: A trajectory analysis with the solution of non-linear Poisson–Boltzmann equation. Colloids Surf A Physicochem Eng Asp 2015. [DOI: 10.1016/j.colsurfa.2015.07.037] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
|
40
|
Kotani H, Kondou N, Ishiguro J, Hisada T, Adachi Y, Ichikawa M, Yoshimura A, Hattori M, Sawaki M, Iwata H. P130 Investigation by questionnaire of the employment of Japanese breast cancer patients. Breast 2015. [DOI: 10.1016/s0960-9776(15)70172-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
41
|
Hisada T, Nakada J, Okumura S, Kondou N, Sawaki M, Yoshimura A, Adachi Y, Ishiguro J, Kotani H, Iwata H. P321 Analgesia with thoracic wall nerve block for breast reconstruction with expander or implant. Breast 2015. [DOI: 10.1016/s0960-9776(15)70351-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
42
|
Zhang Q, Ichimaru N, Higuchi S, Cai S, Hou J, Fujino M, Nonomura N, Kobayashi M, Ando H, Uno A, Sakurai K, Mochizuki S, Adachi Y, Ohno N, Zou H, Xu J, Li XK, Takahara S. Permanent acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system. Gene Ther 2015; 22:217-26. [DOI: 10.1038/gt.2014.119] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2014] [Revised: 11/06/2014] [Accepted: 11/17/2014] [Indexed: 01/27/2023]
|
43
|
Nishida N, Yang X, Takasaki I, Imai K, Kato K, Inoue Y, Imamura T, Miyashita R, Kato F, Yamaide A, Mori M, Saito S, Hara J, Adachi Y, Miyawaki T, Kanegane H. Dysgammaglobulinemia Associated With Glu349del, a Hypomorphic XIAP Mutation. J Investig Allergol Clin Immunol 2015; 25:205-213. [PMID: 26182687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
Abstract
BACKGROUND X-linked lymphoproliferative syndrome type 2 is a rare hereditary immunodeficiency caused by mutations in the XIAP gene. This immunodeficiency frequently results in hemophagocytic lymphohistiocytosis, although hypogammaglobulinemia and dysgammaglobulinemia are also common. OBJECTIVE We identified 17 patients from 12 Japanese families with mutations in XIAP. The Glu349del mutation was observed in 3 patients, each from a different family. Interestingly, these patients exhibited dysgammaglobulinemia but not hemophagocytic lymphohistiocytosis. We conducted an immunological study of patients carrying Glu349del and other mutations to elucidate the pathogenic mechanisms of dysgammaglobulinemia in patients with mutations in the XIAP gene. PATIENTS AND METHODS We performed an immunological study of 2 patients carrying the Glu349del mutation and 8 patients with other mutations. RESULTS Flow cytometry showed that the percentage of memory B cells in patients with a mutation in XIAP was lower than that observed in the healthy controls. The patients with the Glu349del mutation had a lower percentage of memory B cells than those with other mutations. Ig production was reduced in patients with the Glu349del mutation. Increased susceptibility to apoptosis was observed in the patients with other mutations. Susceptibility to apoptosis was normal in patients with Glu349del. Microarray analysis indicated that expression of Ig-related genes was reduced in patients with the Glu349del mutation and that the pattern was different from that observed in the healthy controls or patients with other mutations in XIAP. CONCLUSIONS Patients carrying the Glu349del mutation in the XIAP gene may have a clinically and immunologically distinct phenotype from patients with other XIAP mutations. The Glu349del mutation may be associated with dysgammaglobulinemia.
Collapse
|
44
|
Adachi T, Kitayama M, Nakano T, Adachi Y, Kato S, Nakashima K. Autopsy case of spinocerebellar ataxia type 31 with severe dementia at the terminal stage. Neuropathology 2014; 35:273-9. [PMID: 25495291 DOI: 10.1111/neup.12184] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 10/22/2014] [Indexed: 12/15/2022]
Abstract
Spinocerebellar ataxia type 31 (SCA31) is an autosomal dominant cerebellar ataxia commonly observed in Japan. However, few neuropathological examinations have been conducted. Here we report the case of a 76-year-old Japanese male SCA31 patient. He noticed dysarthria and difficulty walking at 65 years old. His symptoms subsequently deteriorated, although he could still walk with assistance at 70 years. At 73 years, when he could no longer walk, he was admitted to our hospital. He showed severe limb and truncal ataxia. His father and older brother had shown the same symptoms. Brain magnetic resonance imaging showed cerebellar atrophy of the anterior lobe and white matter hyperintensities. He was diagnosed with SCA31 by genetic analysis. Gradually, his cognitive functions and ability to communicate declined. He died of respiratory failure at the age of 76. Neuropathological examination revealed severe Purkinje cell loss that was accentuated in the anterior lobe of the cerebellum. Furthermore, the remaining Purkinje cells showed abnormal processes (that is, halo-like amorphous materials), as has been reported previously. Severe deposition of hyperphosphorylated tau-positive neurites, many senile plaques and amyloid angiopathy were observed in the neocortex. Our findings suggest that in SCA31, accelerated tau and amyloid pathology in the neocortex might induce dementia at the terminal stage.
Collapse
Affiliation(s)
- Tadashi Adachi
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Michio Kitayama
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Toshiya Nakano
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Yoshiki Adachi
- Department of Neurology, National Hospital Organization Matsue Medical Center, Matsue, Japan
| | - Shinsuke Kato
- Department of Neuropathology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Kenji Nakashima
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
| |
Collapse
|
45
|
Ozawa Y, Okamoto K, Adachi Y, Asano M, Tabata K, Funahashi Y, Matsui J. 36 Suppression of metastasis and improvement of drug distribution by eribulin mesylate. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70162-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Matsuoka Y, Adachi Y, Metsugi H, Tokushima T, Adachi Y. [Birt-Hogg-Dubé syndrome with repeated pneumothorax; report of a case]. Kyobu Geka 2014; 67:946-949. [PMID: 25201377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A 36-year-old man had been treated by thoracoscopic bullectomy because of left pneumothorax at another hospital. 2 weeks post-surgery, he was transferred to our hospital because of recurrent left pneumothorax. Chest computed tomography (CT) revealed multiple, irregular-shaped pulmonary cysts of various sizes predominating in the apex of both lungs. Thoracoscopy showed diffuse multiple thinwalled small cysts on the visceral pleura. Small cyst with air leakage was sutured and other cysts were cauterized. He was diagnosed as having Birt-Hogg-Dubé (BHD) syndrome by DNA sequence analysis of his FLCN gene.
Collapse
Affiliation(s)
- Yuki Matsuoka
- Department of Thoracic Surgery, Matsue Medical Center, Matsue, Japan
| | | | | | | | | |
Collapse
|
47
|
Fujita T, Sawaki M, Hattori M, Kondou N, Yoshimura A, Gondou N, Ichikawa M, Kotani H, Adachi Y, Hisada T, Ishiguro J, Iwata H. Risk of Locoregional Recurrence After Mastectomy By Hormone Receptor Status and Her2 Status in Breast Cancer Patients with 1-3 Positive Nodes. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu328.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Ishibashi K, Fukazawa R, Miura NN, Adachi Y, Ogawa S, Ohno N. Diagnostic potential of antibody titres against Candida cell wall β-glucan in Kawasaki disease. Clin Exp Immunol 2014; 177:161-7. [PMID: 24635107 DOI: 10.1111/cei.12328] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/10/2014] [Indexed: 11/28/2022] Open
Abstract
Kawasaki disease (KD) is an acute vasculitis syndrome of unknown aetiology in children. The administration of Candida cell wall antigens induced KD-like coronary vasculitis in mice. However, the responses of KD patients to Candida cell wall antigen are unknown. In this study, we examined the response of KD patients to β-glucan (BG), one of the major fungal cell wall antigens, by measuring the anti-BG titre. In KD patients, the anti-C. albicans cell wall BG titre was higher than that in normal children. The anti-BG titre was also higher in KD patients compared to children who served as control subjects. The efficacy of intravenous immunoglobulin (IVIG) therapy in KD is well established. We categorized the KD patients into three groups according to the therapeutic efficacy of intravenous immunoglobulin (IVIG) and compared the anti-BG titre among these groups. Anti-BG titres were similar in the control group and the non-responsive group. In the fully responsive group, the anti-BG titre showed higher values than those in the normal children. This study demonstrated clinically that KD patients have high antibody titres to Candida cell wall BG, and suggested the involvement of Candida cell wall BG in the pathogenesis of KD. The relationship between IVIG therapy and anti-BG titre was also shown. These results provide valuable insights into the therapy and diagnosis of KD.
Collapse
Affiliation(s)
- K Ishibashi
- Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
49
|
Yasui K, Yabe I, Yoshida K, Kanai K, Arai K, Ito M, Onodera O, Koyano S, Isozaki E, Sawai S, Adachi Y, Sasaki H, Kuwabara S, Hattori T, Sobue G, Mizusawa H, Tsuji S, Nishizawa M, Nakashima K. A 3-year cohort study of the natural history of spinocerebellar ataxia type 6 in Japan. Orphanet J Rare Dis 2014; 9:118. [PMID: 25053188 PMCID: PMC4223818 DOI: 10.1186/s13023-014-0118-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 07/11/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Only a few prospective studies have determined which clinical symptoms and factors are associated with the disease severity of spinocerebellar ataxia type 6 (SCA6). A multicenter longitudinal cohort study was conducted to clarify both the natural history of SCA6 in Japan and the factors influencing disease progression. METHODS Patients were consecutively recruited between 2007 and 2008. Scores from the Scale for the Assessment and Rating of Ataxia (SARA) and Barthel Index (BI) were collected prospectively each year. Additionally, data from the Japan intractable diseases research (IDR) registry were collected both retrospectively, from 2003 to 2006, and prospectively, from 2007 to 2010. As a result, we were able to collect 3 years of retrospective data and 4 years of prospective data during the course of 3 yearly visits. RESULTS Forty-six patients were registered. The follow-up rate of the third year was 93%. The SARA scores worsened significantly each year. Over 3 years, the decline of the SARA scores was 1.33 ± 1.40 points/year. The results of multivariate analysis of the decline of the SARA score were not significant. The IDR scores correlated well with the SARA and BI scores. Kaplan-Meier curves of 7 years of data from the IDR registry illustrated the correlation between the ability to walk and the time course of the disease. CONCLUSIONS Information regarding the progression of ataxia and the decline in the activities of daily living (ADL) in patients with SCA6 was obtained by a 3-year cohort study and a 7-year IDR study. The decline of the SARA score of patients with SCA6 was 1.33 ± 1.40 points/year. The results elucidate the natural history of SCA6, factors influencing disease severity, and utility of data from the IDR registry of Japan.
Collapse
|
50
|
Takimoto T, Kanbayashi Y, Toyoda T, Adachi Y, Furuta C, Suzuki K, Miwa T, Bannai M. 4β-Hydroxywithanolide E isolated from Physalis pruinosa calyx decreases inflammatory responses by inhibiting the NF-κB signaling in diabetic mouse adipose tissue. Int J Obes (Lond) 2014; 38:1432-9. [PMID: 24566854 DOI: 10.1038/ijo.2014.33] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Revised: 01/27/2014] [Accepted: 01/27/2014] [Indexed: 02/03/2023]
Abstract
BACKGROUND Chronic inflammation in adipose tissue together with obesity induces insulin resistance. Inhibitors of chronic inflammation in adipose tissue can be a potent candidate for the treatment of diabetes; however, only a few compounds have been discovered so far. The objective of this study was to find a novel inhibitor that can suppress the inflammatory response in adipose tissue and to elucidate the intracellular signaling mechanisms of the compound. METHODS To find the active compounds, we established an assay system to evaluate the inhibition of induced MCP-1 production in adipocyte/macrophage coculture in a plant extract library. The active compound was isolated by performing high-performance liquid chromatography (HPLC) and was determined as 4β-hydroxywithanolide E (4βHWE) by nuclear magnetic resonance (NMR) and mass spectroscopy (MS) spectral analyses. The effect of 4βHWE on inflammation in adipose tissue was assessed with adipocyte culture and db/db mice. RESULTS During the screening process, Physalis pruinosa calyx extract was found to inhibit production of MCP-1 in coculture strongly. 4βHWE belongs to the withanolide family of compounds, and it has the strongest MCP-1 production inhibitory effect and lowest toxicity than any other withanolides in coculture. Its anti-inflammatory effect was partially dependent on the attenuation of NF-κB signaling in adipocyte. Moreover, in vivo experiments showed that the oral administration of 4βHWE to db/db mice resulted in the inhibition of macrophage invasion and cytokine expression in adipose tissue after 2 weeks of treatment; improved the plasma adiponectin, non-esterified fatty acids and MCP-1 concentrations; and increased glucose tolerance after 3 to 4 weeks of treatment. CONCLUSIONS These results suggest that 4βHWE has anti-inflammatory effect via inhibition of NF-κB activation in adipocyte. Moreover, the attenuation of inflammation in adipocyte has an effect on the inhibition of macrophage accumulation in obese adipose tissue. Consequently, 4βHWE improves impaired glucose tolerance. Thus, 4βHWE is a useful natural anti-inflammatory compound to attenuate progression of diabetes and obesity.
Collapse
Affiliation(s)
- T Takimoto
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - Y Kanbayashi
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - T Toyoda
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - Y Adachi
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - C Furuta
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - K Suzuki
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - T Miwa
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| | - M Bannai
- Frontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan
| |
Collapse
|